
Earnings Insights
AI-generated analysis of quarterly earnings, concall highlights, and financial performance across Indian listed companies.
How to use these insights
Each article is built from earnings call transcripts and structured rank signals. Start with the latest summary, then open the stock page for the full company view, the concall page for quarter-by-quarter commentary, and the rankings dashboard to compare peers.
Kanpur Plastipack Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
Acquisitions like Valex Ventures to add INR 4-5 crore top line on a consolidated basis. Key concall takeaways from Kanpur Plastipack Ltd's Q1 FY26 earnings…
26 May 2026
Kamat Hotels (India) Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
Seasonal and regional variations affect occupancy, with leisure destinations taking longer (6-9 months) to achieve optimal utilization (~70% occupancy). Key…
26 May 2026
Kamat Hotels (India) Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
Despite recent revenue dips due to monsoon, renovations, and subsidiary performance, management is confident of crossing INR 400 crore revenue in FY 2026. Key…
26 May 2026
Kamat Hotels (India) Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
The company plans to expand room inventory from approximately 1,850 to 2,500 operational rooms within the year, a ~35% increase. Key concall takeaways from…
26 May 2026
Kamat Hotels (India) Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
65%; major cities like Mumbai and Delhi can see occupancies in the 70-80% range. Key concall takeaways from Kamat Hotels (India) Ltd's Q4 FY25 earnings call…
26 May 2026
KAMATHOTEL Q3 FY25 earnings call: Margins & Order Book | Arthneeti
Q3 FY25
Direct booking channels and repeat customers (34% repeat rate) contribute to sustainable revenue growth. Key concall takeaways from KAMATHOTEL's Q3 FY25…
26 May 2026
Jyoti Resins and Adhesives Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
Current Q1 FY26 volume showed a 3% de-growth, but efforts ongoing to recover in remaining quarters (Page 27). Key concall takeaways from Jyoti Resins and…
26 May 2026
Jyoti Resins and Adhesives Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
The goal is to reach INR 500 crore revenue by FY27 through a mix of geographic expansion and deepened penetration in existing markets. Key concall takeaways…
26 May 2026
Jindal Drilling & Industries Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
. Key concall takeaways from Jindal Drilling & Industries Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
26 May 2026
Jindal Drilling & Industries Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
Company currently has a net cash position of INR112 crores and strong operational profitability. Key concall takeaways from Jindal Drilling & Industries Ltd's…
26 May 2026
Jindal Drilling & Industries Q3 FY25 earnings call: Revenue & Margins | Arthneeti
Q3 FY25
Market leadership and consolidation of rigs into Jindal Drilling will potentially improve EBITDA margins further from current 30-35%. Key concall takeaways…
26 May 2026
Jain Irrigation Systems Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
Retail sales showed strong growth (24% this quarter), and future growth will be primarily retail-driven with better working capital efficiency. Key concall…
26 May 2026
Jain Irrigation Systems Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
Hi-tech division (micro irrigation and tissue culture) to grow strongly, with tissue culture potentially growing 20%-30%. Key concall takeaways from Jain…
26 May 2026
Jagsonpal Pharmaceuticals Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
Margins improved with operational resilience; EBITDA margins were 22.6% for nine months FY '26. Key concall takeaways from Jagsonpal Pharmaceuticals Ltd's Q3…
26 May 2026
Jagsonpal Pharmaceuticals Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
Around 9%-10% of growth is organic, with the rest from full-quarter contribution of acquisitions. Key concall takeaways from Jagsonpal Pharmaceuticals Ltd's Q1…
26 May 2026
Jagsonpal Pharmaceuticals Q3 FY25 earnings call: Revenue & Margins | Arthneeti
Q3 FY25
Growth drivers include approximately one-third volume growth, one-third price increases (3-5%), and one-third new product launches. Key concall takeaways from…
26 May 2026
Insecticides India Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
Emphasis on disciplined capital allocation with focus on increasing capital efficiency and improving organizational revenue, ROCE, and ROE by 6-7% over three…
26 May 2026
Insecticides India Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
150 crore sales in exports this year. Key concall takeaways from Insecticides India Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
26 May 2026
Insecticides India Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
10-12 crore in FY'26, with potential multiplication in subsequent years (Page 9-12). Key concall takeaways from Insecticides India Ltd's Q4 FY25 earnings call…
26 May 2026
BirlaNu Q4 FY25: Revenue ₹100 Cr | Arthneeti
Q4 FY25
OPVC plant Phase 1 capacity to be around 5,000 tons/year with revenue potential north of Rs.100 crore. Key concall takeaways from BirlaNu Ltd's Q4 FY25…
26 May 2026
Arthneeti Pro · Annual
Every earnings call this season,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access